Company news

Veracyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

May 15, 2022

Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting

May 11, 2022

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

May 11, 2022

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

May 3, 2022

Veracyte Announces First Quarter 2022 Financial Results

May 2, 2022

Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis

May 1, 2022

Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference

April 27, 2022

Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference

April 25, 2022

Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022

April 18, 2022

Veracyte to Participate in the Cowen 42nd Annual Health Care Conference

February 28, 2022

Veracyte Appoints Annie McGuire as General Counsel

February 27, 2022

Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results

February 27, 2022

Veracyte Appoints Jonathan Wygant as Chief Accounting Officer

February 21, 2022

Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022

February 14, 2022

New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer

February 13, 2022

Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 7, 2022

Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium

January 30, 2022

New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer

January 23, 2022

Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision

January 5, 2022

Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

December 13, 2021

Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

November 23, 2021

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021

November 12, 2021

Veracyte Announces Third Quarter 2021 Financial Results

November 8, 2021

Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia

November 4, 2021

New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis

November 2, 2021

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities

November 1, 2021

New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

October 25, 2021

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

October 24, 2021

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

October 13, 2021

New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

October 12, 2021

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

October 11, 2021

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

October 10, 2021

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

October 10, 2021

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

October 5, 2021

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

September 13, 2021

Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

August 31, 2021

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

August 30, 2021

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year

August 22, 2021

Veracyte Completes Acquisition of HalioDx

August 2, 2021

Veracyte Announces Second Quarter 2021 Financial Results

July 28, 2021

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

July 26, 2021

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

July 11, 2021

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

July 7, 2021

Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

July 7, 2021

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team

June 30, 2021

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

June 13, 2021

Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder

June 3, 2021

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

June 1, 2021

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth

May 31, 2021

Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples

May 25, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.